Literature DB >> 8827714

The MDM2 oncoprotein binds specifically to RNA through its RING finger domain.

B Elenbaas1, M Dobbelstein, J Roth, T Shenk, A J Levine.   

Abstract

BACKGROUND: The cellular mdm2 gene has transforming activity when overexpressed and is amplified in a variety of human tumors. At least part of the transforming ability of the MDM2 protein is due to binding and inactivating the p53 tumor suppressor protein. Additionally, this protein forms a complex in vivo with the L5 ribosomal protein and its associated 5S ribosomal RNA and may be part of a ribosomal complex.
MATERIALS AND METHODS: A RNA homopolymer binding assay and a SELEX procedure have been used to characterize the RNA-binding activity of MDM2.
RESULTS: The MDM2 protein binds efficiently to the homopolyribonucleotide poly(G) but not to other homopolyribonucleotides. This binding is independent of the interaction of MDM2 with the L5 protein, which occurs through the central acidic domain of MDM2. An RNA SELEX procedure was performed to identify specific RNA ligands that bind with high affinity to the human MDM2 (HDM2) protein. After 10 rounds of selection and amplification, a subset of RNA molecules that bound efficiently to HDM2 was isolated from a randomized pool. Sequencing of these selected ligands revealed that a small number of sequence motifs were selected. The specific RNA binding occurs through the RING finger domain of the protein. Furthermore, a single amino acid substitution in the RING finger domain, G446S, completely abolishes the specific RNA binding.
CONCLUSIONS: These observations, showing that MDM2 binds the L5/5S ribosomal ribonucleoprotein particle and can also bind to specific RNA sequences or structures, suggest a role for MDM2 in translational regulation in a cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827714      PMCID: PMC2230168     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  45 in total

1.  Identification and preliminary characterization of a protein motif related to the zinc finger.

Authors:  R Lovering; I M Hanson; K L Borden; S Martin; N J O'Reilly; G I Evan; D Rahman; D J Pappin; J Trowsdale; P S Freemont
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

2.  Selective enrichment of RNA species for tight binding to Escherichia coli rho factor.

Authors:  D Schneider; L Gold; T Platt
Journal:  FASEB J       Date:  1993-01       Impact factor: 5.191

3.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.

Authors:  J D Oliner; J A Pietenpol; S Thiagalingam; J Gyuris; K W Kinzler; B Vogelstein
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  Saccharomyces cerevisiae RAD5-encoded DNA repair protein contains DNA helicase and zinc-binding sequence motifs and affects the stability of simple repetitive sequences in the genome.

Authors:  R E Johnson; S T Henderson; T D Petes; S Prakash; M Bankmann; L Prakash
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

5.  p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

Authors:  F S Leach; T Tokino; P Meltzer; M Burrell; J D Oliner; S Smith; D E Hill; D Sidransky; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

6.  MDM2 gene amplification in metastatic osteosarcoma.

Authors:  M Ladanyi; C Cha; R Lewis; S C Jhanwar; A G Huvos; J H Healey
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

7.  The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.

Authors:  C A Finlay
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

8.  An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif.

Authors:  N E Crook; R J Clem; L K Miller
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

Authors:  G Reifenberger; L Liu; K Ichimura; E E Schmidt; V P Collins
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

10.  Primary structure and binding activity of the hnRNP U protein: binding RNA through RGG box.

Authors:  M Kiledjian; G Dreyfuss
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

View more
  55 in total

1.  Stress signals utilize multiple pathways to stabilize p53.

Authors:  M Ashcroft; Y Taya; K H Vousden
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 2.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

5.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

6.  Perturbation of 60 S ribosomal biogenesis results in ribosomal protein L5- and L11-dependent p53 activation.

Authors:  Xiao-Xin Sun; Yue-Gang Wang; Dimitris P Xirodimas; Mu-Shui Dai
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

7.  Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence.

Authors:  M Dobbelstein; J Roth; W T Kimberly; A J Levine; T Shenk
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

8.  The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.

Authors:  Masha V Poyurovsky; Christina Priest; Alex Kentsis; Katherine L B Borden; Zhen-Qiang Pan; Nikola Pavletich; Carol Prives
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

9.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

10.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.